Tacrolimus Drug–Drug Interaction with Nirmatrelvir/Ritonavir (Paxlovid™) Managed with Phenytoin
- 19 December 2022
- journal article
- case report
- Published by Springer Nature in Journal of Medical Toxicology
- Vol. 19 (1) , 45-48
Abstract
Introduction The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or COVID-19) pandemic has had a significant impact on communities and health systems. The Federal Drug Administration (FDA) authorized Pfizer’s nirmatrelvir/ritonavir (Paxlovid™) through an EUA for the treatment of mild to moderate cases of COVID-19 at high risk for progression to severe disease. Patients with a history of transplant who test positive for COVID-19 are considered high risk because of their immunosuppression and are therefore candidates for nirmatrelvir/ritonavir. Case Report This is a case of a 67-year-old female with a past medical history of orthotopic heart transplant who received tacrolimus as part of her immunosuppressive regimen. She originally presented with complaints of dyspnea and cough for several days in the setting of COVID-19. The patient was started on nirmatrelvir/ritonavir due to her high risk for progression to severe disease. Four days after starting nirmatrelvir/ritonavir, she presented to the ED for slowed speech, fatigue, weakness, and loss of appetite. Upon admission she was found to have a supratherapeutic tacrolimus level of 176.4 ng/mL and an acute kidney injury. In this case, phenytoin was used as a CYP3A4 inducer to quickly decrease the tacrolimus level to within therapeutic range. Conclusion This case highlights the strong and important drug–drug interaction between tacrolimus and nirmatrelvir/ritonavir leading to toxic levels of tacrolimus. It also demonstrates the utility and effectiveness of phenytoin as a “rescue” medication for tacrolimus toxicity.Keywords
This publication has 11 references indexed in Scilit:
- Paxlovid (Nirmatelvir/Ritonavir) and Tacrolimus Drug-Drug Interaction in a Kidney Transplant Patient with SARS-2-CoV infection: A Case ReportTransplantation Proceedings, 2022
- Use of phenytoin for treatment of tacrolimus toxicity with superimposed sepsisBMJ Case Reports, 2020
- Treatment of Acute Tacrolimus Toxicity with Phenytoin in Solid Organ Transplant RecipientsCase Reports in Transplantation, 2013
- Enzyme induction with antiepileptic drugs: Cause for concern?Epilepsia, 2012
- Calcineurin Inhibitor NephrotoxicityClinical Journal of the American Society of Nephrology, 2009
- HepaRG Cells as an in Vitro Model for Evaluation of Cytochrome P450 Induction in HumansDrug Metabolism and Disposition, 2008
- Pharmacodynamics of Carbamazepine-mediated Induction of CYP3A4, CYP1A2, and Pgp as Assessed by Probe Substrates Midazolam, Caffeine, and DigoxinClinical Pharmacology & Therapeutics, 2007
- Dysarthria and apraxia of speech associated with FK-506 (tacrolimus).1996
- Dysarthria and Apraxia of Speech Associated With FK-506(Tacrolimus)Mayo Clinic Proceedings, 1996
- Neurologic complications of FK 506.1991